August 13, 2020
RedDress was selected among 20 Israeli startup companies as one of the Top Promising Israeli Startups of 2020 – a humbling honor for the RedDress team and its founders, Dr. Igal Kushnir and his son, Alon Kushnir. For its list, The Marker selects 20 Israeli startups that confront the greatest challenges facing humanity. For RedDress, […]
February 18, 2020
PONTE VEDRA BEACH, Fla., Feb. 19, 2020 - RedDress, a privately held, Israel and U.S. based company, today announced the U.S. launch of ActiGraft, the first wound treatment that transforms – in real time – a patient's blood into an autologous whole blood clot tissue. Once applied, ActiGraft serves as a protective covering, biologic scaffold […]
November 19, 2019
Pardes-Hanna, Israel, November 19, 2019 – RedDress®, an Israel-based company with the goal of developing more effective, natural and economically viable treatment for chronic wounds, advanced to the final round of the 2019 "Chuangxiang China" Anhui Innovation & Entrepreneurship Competition (Tel Aviv Division), hosted in Tel Aviv, Israel. According to Xinhua, a total of 110 […]
November 11, 2019
Pardes-Hanna, Israel November 11, 2019 – RedDress®, an Israel-based company with the goal of developing more effective, natural and economically viable treatment for chronic wounds, today announced the launch of its redesigned website. The enhanced website reddressmedical.com features improved functionality, streamlined navigation, and rich content geared toward patients and professionals alike, with essential information about […]
June 18, 2019
PARDES-HANNA, Israel, June 18, 2019 -- RedDress’s ActiGraft is one of the medical innovations that was showcased in front of thousands of healthcare providers at Premier Inc.’s 2019 Breakthroughs Conference and Exhibition on June 18.RedDress’s ActiGraft was debuted during the conference’s 11th annual Innovation Celebration, an event recognizing advancements in healthcare and highlighting suppliers dedicated […]
June 14, 2019
PARDES-HANNA, Israel, June 14, 2018 /PRNewswire/ -- RedDress® Ltd announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RD1 system. RD1 is an innovative wound care product which enables health care providers to produce in real time, in vitro whole blood clots, for use as a chronic wound […]
